Back to results
US 2003/0148507 A1Published application
RNA interference mediated inhibition of prostaglandin D2 receptor (PTGDR) and prostaglandin D2 synthetase (PTGDS) gene expression using short interfering RNA
AssigneeRibozyme Pharmaceuticals, Inc.
InventorsKathy Fosnaugh, James A. McSwiggen
Life of this patent
Estimating the term…
Abstract
The present invention concerns methods and reagents useful in modulating prostaglandin D2 receptor (PTGDR) and/or prostaglandin D2 synthetase (PTGDS) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small interfering RNA (siRNA) molecules capable of mediating RNA interference (RNAi) against PTGDR and/or PTGDS.
Claims36
A short interfering RNA (siRNA) molecule that down regulates expression of a prostaglandin D2 receptor PTGDR gene by RNA interference.
Dependencies are inferred from the claim text.